News about Global Pharma

Remedium Lifecare Unveils 4-Point Growth Strategy

Remedium Lifecare Ltd. has unveiled a 4-point strategic roadmap – spanning advanced manufacturing, global expansion, R&D innovation, and product diversification.

Global Pharma | 02/09/2025 | By Mrinmoy Dey |  213

Asston Pharmaceuticals Secures International Supply Order Worth INR 2.65 Crore

Asston Pharmaceuticals has received an order from a leading international pharmaceutical company to supply a range of pharma products worth INR 2.65 crore

Global Pharma | 02/09/2025 | By Dineshwori |  253

Four Drugs in Race for First Bispecific ADC Approval: GlobalData

With 21 global approvals, ADCs generated USD 13.6 billion in 2024. BsADCs represent further opportunities in this field, by leveraging bi-specific antibodies that simultaneously bind two distinct targets.

Global Pharma | 02/09/2025 | By Dineshwori |  367

Accro Bioscience and Fosun Pharma Enter Licensing Deal for AC-201 in Greater China

Accro Bioscience has granted Fosun Pharma exclusive rights to develop, manufacture, and commercialise AC-201 — its independently developed, highly selective TYK2/JAK1 inhibitor — in Greater China (including the Chinese Mainland, Hong Kong SAR, and Macau SAR).

Global Pharma | 01/09/2025 | By Dineshwori |  355

Bausch Health Expands Dermatology Portfolio with YUN Probiotherapy Launch in Poland

Following its partnership with Belgian biotech company YUN NV last June, Bausch Health has launched the YUN ACN skincare line in Poland, expanding its dermatology portfolio.

Global Pharma | 01/09/2025 | By Dineshwori |  741

FDA Approves Eisai and Biogen's At-Home Alzheimer's Injection Leqembi IQLIK

Leqembi IQLIK, delivering a 360 mg dose within 15 seconds, will be available from 6 October, 2025, at a list price of USD 19,500 annually for a pack of pre-filled autoinjectors.

Global Pharma | 30/08/2025 | By Dineshwori |  703

Foresee Pharmaceuticals Secures US FDA Approval for CAMCEVI ETM for Treating Advanced Prostate Cancer

Foresee Pharmaceuticals has received US FDA approval for CAMCEVI ETM (21 mg) as a treatment for advanced prostate cancer.

Global Pharma | 30/08/2025 | By Mrinmoy Dey |  508

US FDA Clears Sanofi's Wayrilz, First BTK Inhibitor for ITP

The US FDA approval was based on the pivotal LUNA 3 phase-III study, in which Sanofi’s Wayrilz met the primary and secondary endpoints, showing a positive impact on sustained platelet counts and other ITP symptoms.

Global Pharma | 30/08/2025 | By Dineshwori |  313

Teva Pharmaceuticals Launches First Generic Version of Saxenda in US

The first generic version of Saxenda, Liraglutide injection, is approved for adults with obesity or overweight who have weight-related medical conditions, as well as for paediatric patients aged 12 to 17 years weighing more than 60 kg with obesity.

Global Pharma | 30/08/2025 | By Dineshwori |  867

OPTEL Acquires Vanguard Robotics to Accelerate Innovation in Pharma Automation

OPTEL Group has acquired Vanguard Robotics to strengthen its pharmaceutical automation portfolio with advanced end-of-line cobot solutions.

Global Pharma | 29/08/2025 | By Mrinmoy Dey |  320